Antibodies Leading The Combination Cancer Immunotherapy Market

Release Date: 14-Jun-2022

Global Combination Cancer Immunotherapy Market Opportunity and Clinical Trials Insight 2028 Report Highlights:




Download Report:


Therapeutic antibodies have emerged out to be shining star in the management of wide range of cancers owing to their novel mechanism of action and high specificity towards the receptors which is expressed on the cancer cell lines. Since their introduction into the market, these have occupied a dominant share in the global cancer therapeutics market. Till date, a cocktail of antibody therapeutics including monoclonal antibodies, immune checkpoint inhibitors, bispecific antibodies, and antibody drug conjugates have gained entry into the market which have shown huge adoption among the cancer patients.  


Despite their huge clinical success, the research is still ongoing for the development of more efficient approaches to target the complex nature of disease. In last few years, combination cancer immunotherapy has gained momentum in the market which significantly improved the survival outcomes in cancer patients by combining two or more drugs which have synergistic mechanism of action. Antibody therapeutics are one of the leading components in combination cancer immunotherapy market which have shown additive effect in combination with wide range of therapeutics including chemotherapy, radiotherapy, small molecule inhibitors, or other immunotherapeutic approaches. Till date, a cocktail of antibody combination therapies have been granted approval for the management of cancers.


The encouraging of these drugs has surged the further research and development activities in this domain. The key players in the market have entered into partnerships, collaboration, or joint ventures to analyze different combinations to enhance the efficacy of antibodies as combination therapies. For example in 2021, Immunetep announced new collaboration and supply agreement with Merck to conduct phase-I/II INSIGHT-005 clinical trials in patients with solid tumors. The trial will evaluate the feasibility, safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), when given in combination with bintrafusp alfa (M7824), an investigational bifunctional fusion protein immunotherapy being jointly developed by Merck and GlaxoSmithKline.


Gilead Sciences also entered into two clinical trial collaborations and supply agreements with Merck to evaluate the combination of Trodelvy and Keytruda in first line metastatic non-small cell lung cancer. As part of this collaboration, Merck will sponsor phase-III clinical study of combination therapies. Additionally, the companies recently established an agreement whereby Gilead will sponsor a Phase 2 signal-seeking study evaluating combinations that include pembrolizumab in first-line non-small cell lung cancer.


In addition to this, researchers are also utilizing investigational trispecific antibodies as combination therapies. For instance in 2022, Harpoon Therapeutics has announced clinical trial agreement with Roche to evaluate the combination of HPN328 and atezolizumab in solid tumors. HPN328 is an investigational DLL3 targeting trispecific T cell activating construct (TriTAC) developed by Harpoon Therapeutics. The large number of ongoing clinical trials in the global market suggests the promising future of antibodies in combination cancer immunotherapy market.


Currently, the market is mainly dominated by immune checkpoint targeting antibodies. Wide range of PD-1/PD-L1 and CTLA-4 immune checkpoint blockade has entered the market to be utilized in combination with each other or other chemotherapeutic regimens. Opdivo and Yervoy is one of the promising combination immunotherapy which has been approved for the management of lung cancer and is also undergoing trials in several other therapeutic indications. Apart from PD-1 and CTLA-4 immune checkpoint, research studies have also identified several co-stimulatory immune checkpoint including Tim-3, LAG-3, TIGIT, and others which when combined with approved immune checkpoint blockade, enhance their efficacy and overcome the limitation of drug resistance.


As per our report findings, the global combination cancer immunotherapy market is expected to surpass US$ 18 Billion by 2028. The rising adoption of immunotherapy among cancer patients and the promising response of combination therapy over monotherapy are the primary factors propelling the growth of market during the forecast period.




Neeraj Chawla

Kuick research

Research Head


Need custom market research solution? We can help you with that too.